evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4 questions · 4 findings · 1 reviews · Oral medicine and oral cancer

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 4 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Anticonvulsants (gabapentin + alpha lipoic acid) vs placebo

Somnolence · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether anticonvulsants (gabapentin + alpha lipoic acid) changes adverse effects: drowsiness compared with placebo (very low certainty).

1 finding from 1 review

Anticonvulsants (gabapentin + alpha lipoic acid) vs placebo

Adverse effects: mild headache · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether anticonvulsants (gabapentin + alpha lipoic acid) changes adverse effects: mild headache compared with placebo (very low certainty).

1 finding from 1 review

Anticonvulsants (gabapentin 300 mg/day, +/- alpha lipoic acid) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether anticonvulsants (gabapentin 300 mg/day, +/- alpha lipoic acid) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

1 finding from 1 review

Anticonvulsants (gabapentin + alpha lipoic acid) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
  • Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes
    short-term (up to 3 months) · gabapentin with adjunctive ALA
    SoF2 subgroup. Gabapentin + adjunctive ALA vs placebo forms one of two subgroups of the anticonvulsant symptom-relief estimate (RR 4.00, 2.09 to 7.67); no between-subgroup difference vs gabapentin alone; 100…
    1 study · 40 participants
    Very low